Literature DB >> 22245989

In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection.

Guofeng Zhang1, Feng Zhou, Bin Gu, Chuanling Ding, Dongju Feng, Fangyi Xie, Jinfeng Wang, Chun Zhang, Qingxian Cao, Yinlai Deng, Weixing Hu, Kun Yao.   

Abstract

Enterovirus 71(EV71) causes recurring outbreaks of hand, foot and mouth disease and encephalitis leading to complications or death in young children. More effective antiviral drugs are needed to prevent or reduce EV71-related disease and complications. However, there are no standard models currently in use to evaluate activity against EV71 infection both in vitro and in vivo. In this study, the activity of ribavirin and pleconaril against EV71 infection was evaluated in two models. An in vitro EV71 infection model was developed in RD cells, and an in vivo EV71 infection model was applied. Ribavirin and pleconaril effectively increased the viability of infected cells. Pleconaril reduced the morbidity and mortality of one-day-old infected mice, but ribavirin did not protect the infected mice. In all, the results demonstrated that infected cells and infected mice can be used to evaluate antiviral activity of ribavirin and pleconaril against EV71 infection in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245989     DOI: 10.1007/s00705-011-1222-6

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  26 in total

1.  Ribavirin as a curative and prophylactic agent against foot and mouth disease virus infection in C57BL/6 suckling and adult mice model.

Authors:  Patel Nikunjkumar; Ramasamy Periyasamy Tamil Selvan; Veerakyathappa Bhanuprakash
Journal:  Virusdisease       Date:  2021-10-20

2.  Enterovirus A71 antivirals: Past, present, and future.

Authors:  Jun Wang; Yanmei Hu; Madeleine Zheng
Journal:  Acta Pharm Sin B       Date:  2021-08-20       Impact factor: 14.903

3.  Chronic meningoencephalitis caused by Echo virus 6 in a patient with common variable immunodeficiency : Successful treatment with pleconaril.

Authors:  Igor Radanović; Deni Rkman; Paulo Zekan; Marko Kutleša; Bruno Baršić
Journal:  Wien Klin Wochenschr       Date:  2017-11-07       Impact factor: 1.704

4.  Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture.

Authors:  Sara Sadeghipour; Emily J Bek; Peter C McMinn
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

5.  The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.

Authors:  Aloys Tijsma; David Franco; Simon Tucker; Rolf Hilgenfeld; Mathy Froeyen; Pieter Leyssen; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

6.  In vitro antiviral efficacy of pleconaril and ribavirin on foot-and-mouth disease virus replication.

Authors:  Sarkar Soumajit; Ramasamy Periyasamy Tamil Selvan; Veerakyathappa Bhanuprakash
Journal:  Virusdisease       Date:  2019-12-05

7.  Fatal Enteroviral Encephalitis in a Patient with Common Variable Immunodeficiency Harbouring a Novel Mutation in NFKB2.

Authors:  Charlotte A Slade; Catriona McLean; Thomas Scerri; Tran Binh Giang; Steven Megaloudis; Alexander Strathmore; Jessica C Tempany; Katherine Nicholls; Colleen D'Arcy; Melanie Bahlo; Philip D Hodgkin; Jo A Douglass; Vanessa L Bryant
Journal:  J Clin Immunol       Date:  2019-03-29       Impact factor: 8.542

8.  Formononetin inhibits enterovirus 71 replication by regulating COX- 2/PGE₂ expression.

Authors:  Huiqiang Wang; Dajun Zhang; Miao Ge; Zhuorong Li; Jiandong Jiang; Yuhuan Li
Journal:  Virol J       Date:  2015-03-01       Impact factor: 4.099

Review 9.  Strategies to develop antivirals against enterovirus 71.

Authors:  Rei-Lin Kuo; Shin-Ru Shih
Journal:  Virol J       Date:  2013-01-22       Impact factor: 4.099

10.  Potential Virus Involvement in Alzheimer's Disease: Results from a Phase IIa Trial Evaluating Apovir, an Antiviral Drug Combination.

Authors:  Nina Lindblom; Lars Lindquist; Jacob Westman; Mikael Åström; Roger Bullock; Suzanne Hendrix; Lars-Olof Wahlund
Journal:  J Alzheimers Dis Rep       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.